london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Successful use of Intravitreal bevacizumab (Avastin) in a paediatric case of secondary (traumatic) choroidal neovascular membrane (CNVM)

Poster Details

First Author: V.Prabhu INDIA

Co Author(s):                      0   0 0   0 0   0 0   0 0

Abstract Details


To report successful use of intravitreal bevacizumab (Avastin) in a young boy with choroidal neovascular membrane (CNVM) secondary to traumatic choroidal rupture .


A 8 year old boy presented with defective vision in right eye (RE) following blunt trauma 1 year back . No history of redness ,pain, watering . No history of any previous ocular intervention or treatment taken for same .


On examination BCVA in RE was hand movements close to face ; LE 6/6. The pupillary reactions were normal and slit-lamp biomicroscopic examination of anterior segment was normal in both eyes . Fundus examination of RE showed yellowish white to orange red streak shaped lesion annular to fovea with pigmented margins with retinal hemorrhage in the fovea. LE fundus examination was normal. A clinical diagnosis of RE active CNVM secondary to choroidal rupture ; LE was normal was made . BE IOP was normal . OCT RE confirmed diagnosis . Taking into consideration 1 year history and difficulty in predicting which will progress to permanent visual loss and which will regress without treatment, single injection of Bevacizumab (Avastin) in dose of 1.25mg (0.05ml) was administered intravitreally under aseptic precautions (after fully informed consent). No complication during or after procedure was noted.


Near complete regression of CNVM (hemmorhage) and BCVA in RE -- improved to 6/60 at last follow up at 6 months following the injection .


Intravitreal bevacizumab (Avastin) was safely injected in a case of pediatric traumatic CNVM with favourable outcome. Long term safety and appropriate dosage of lntravitreal bevacizumab needs to be studied.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy